Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9864614 | 0.76 | KMT2A (0.40) | KMT2AUSP2MAPTCYP1A2ALDH1A1 | |
| SCHEMBL2028506 | 0.74 | KMT2A (0.44) | KMT2AUSP2MAPTGAAPKM | |
| SCHEMBL2029380 | 0.74 | HTT (0.41) | KMT2AUSP2MAPTGAAPKM | |
| SCHEMBL4032310 | 0.72 | PKM (0.40) | KMT2AMAPTGAAPKMCYP1A2 | |
| SCHEMBL370542 | 0.71 | MAPK1 (0.49) | KMT2AUSP2MAPTGAACYP1A2 | |
| SCHEMBL4237820 | 0.70 | CYP1A2 (0.40) | KMT2AMAPTCYP1A2ALDH1A1KDM4E | |
| SCHEMBL3369577 | 0.70 | KMT2A (0.44) | KMT2AUSP2MAPTGAAPKM | |
| SCHEMBL9881652 | 0.69 | MAPK1 (0.45) | KMT2AMAPTGAACYP1A2ALDH1A1 | |
| SCHEMBL12381778 | 0.69 | KMT2A (0.46) | KMT2AUSP2MAPTGAACYP1A2 | |
| SCHEMBL12582170 | 0.69 | CYP1A2 (0.42) | MAPTGAAPKMCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| EP-1896465-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | Takeda Cambridge Limited (GB) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007000582-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007000582-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | GNRHR, GHRHR, FSHR | KMT2A 1474/4885USP2 3167/4885MAPT 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.